Further trials sought for MRI (magnetic resonance imaging) contrast agent:
This article was originally published in Clinica
EPIX Medical and Mallinckrodt will seek US approval to begin Phase III trials of an injectable MRI contrast agent for detecting peripheral vascular disease following successful Phase II studies. The agent, called MS-325, was compared with the current X-ray angiography procedure and had an 82% accuracy in identifying clinically significant stenosis. EPIX, based in Cambridge, Massachusetts, said the agent could provide a minimally invasive way of visualising the peripheral vasculature early on in a patient's assessment and reduce the serious side-effects and complications associated with the highly invasive X-ray angiography procedure.